Tag: medication safety
-
Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection
Fresenius Kabi has issued a voluntary nationwide recall of three lots of Famotidine Injection USP, 20 mg per 2 mL (10 mg/mL), after laboratory testing identified an out‑of‑specification impurity result in a single lot. The recall is precautionary and intended to protect patients and maintain supply-chain integrity while further investigations continue.1 Summary of the recall
-
FDA Recall: Over 480K bottles of Teva’s Prazosin Hydrochloride
Teva Pharmaceuticals USA initiated a voluntary, nationwide recall of multiple lots of Prazosin Hydrochloride capsules after laboratory testing found levels of an N‑nitroso impurity (designated N‑nitroso Prazosin impurity C) above the FDA’s acceptable intake limit calculated using the Carcinogenic Potency Categorization Approach (CPCA). The agency classified the recall as Class II, indicating that use of
-
FDA Recalls 141,984 Bottles of Atorvastatin Calcium After Failed Dissolution Testing
On 10 October 2025 the U.S. Food and Drug Administration (FDA) classified a nationwide recall of Atorvastatin Calcium tablets, initiated by Ascend Laboratories, LLC, as a Class II recall because multiple lots “failed dissolution specifications,” affecting 141,984 bottles distributed across the United States. The recalled product is a generic formulation of atorvastatin (a statin widely
-
A Second Opinion on medications: why a data-driven review matters
Every year millions of people begin new prescriptions without a formal, evidence-based second opinion. That single decision can affect treatment effectiveness, quality of life, risk of adverse events, and out-of-pocket cost. A science-based second opinion on medications combines personalized clinical evidence, drug-safety data, and cost information to reduce harms and improve outcomes. This article explains